Mouse Tumor Biology Database (MTB)
MTB Home   Help
Search for Help
 
in these sections
Search Forms
Tumor
Strain
Genetics
Pathology Images
Reference
Advanced
Search MTB Using Human Genes
Gene Expression Data Sets

Additional Resources
new PDX Like Me
PDX Finder
PDX Model Search
Faceted Tumor Search
Dynamic Tumor Frequency Grid
Other Cancer Websites
Immunohistochemistry
Lymphoma Pathology

Mouse Genome Informatics
The Jackson Laboratory
Citing These Resources
Warranty Disclaimer
& Copyright Notice

Send Questions and
Comments to User Support.

Last Database Update
2019-12-01
MTB 3.0
 
HelpHelp and Documentation Reference Detail  
Reference
Title: Genetic and epigenetic silencing of microRNA-203 enhances ABL1 and BCR-ABL1 oncogene expression.
Authors: Bueno MJ; Perez de Castro I; Gomez de Cedron M; Santos J; Calin GA; Cigudosa JC; Croce CM; Fernandez-Piqueras J; Malumbres M
Journal: Cancer Cell
Volume: 13
Issue: 6
Year: 2008
Pages: 496-506
Abstract: The mammalian genome contains several hundred microRNAs that regulate gene expression through modulation of target mRNAs. Here, we report a fragile chromosomal region lost in specific hematopoietic malignancies. This 7 Mb region encodes about 12% of all genomic microRNAs, including miR-203. This microRNA is additionally hypermethylated in several hematopoietic tumors, including chronic myelogenous leukemias and some acute lymphoblastic leukemias. A putative miR-203 target, ABL1, is specifically activated in these hematopoietic malignancies in some cases as a BCR-ABL1 fusion protein (Philadelphia chromosome). Re-expression of miR-203 reduces ABL1 and BCR-ABL1 fusion protein levels and inhibits tumor cell proliferation in an ABL1-dependent manner. Thus, miR-203 functions as a tumor suppressor, and re-expression of this microRNA might have therapeutic benefits in specific hematopoietic malignancies.
Additional
Information
in MTB
Tumor Records (3)
Strains (2)
Other
Accession
IDs
J:138632  Mouse Genome Informatics
18538733  National Library of Medicine/PubMed